Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
September 29, 2008
- NEW PRODUCTS／Kyowa Medex Launches New Reagent to Determine HDL-C
September 29, 2008
- NEW PRODUCT／Julina Launched as Japan's First Oral Estradiol Product
September 29, 2008
- Will Distribution Practices Be Improved? Part 3
September 29, 2008
- Kissei Licenses Monoclonal Antibody from Y's Therapeutics
September 22, 2008
- Global Market for Monoclonal Antibodies to Expand to $49 Bil. in 2013: Datamonitor
September 22, 2008
- Eli Lilly Japan Aims at $1 Bil. in 2010, $2Bil. in 2015: Mr Zulueta
September 22, 2008
- Delegates Criticize JPA Leaders over Qualification for Store Managers
September 22, 2008
- REGULATORY NEWS IN BRIEF
September 22, 2008
- NEW PRODUCTS
September 22, 2008
- Bayer to Begin PIII Trial of Rivaroxaban Ahead of Schedule
September 22, 2008
- Growell HD to Open More Drugstores with Dispensing Services
September 22, 2008
- Yakult Applies for New Indication for Oxaliplatin
September 22, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 22, 2008
- Approval May Be Delayed due to Deficiency in Application Dossiers: PMDA Reviewer
September 22, 2008
- OPINION／Getting to the Honne of the Matter: Part Two Turning Frustration into Success
September 22, 2008
- Chugai Relaxes Post-Marketing Safety Measures for Avastin
September 22, 2008
- R&D NEWS IN BRIEF
September 22, 2008
- More PE Specialists Needed to Enhance PM Safety Measures: Mr Kokan
September 22, 2008
- SEMINAR／New Drugs for Diabetic Nephropathy Needed: JHSF Seminar
September 22, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…